Parvez Mantry MD AGAF, FAASLD

Gastroenterology•Dallas, TX

Advanced Endoscopic Interventional, Hepatology & Liver Transplantation

Physician

Join to View Full Profile

1411 N Beckley AvePav Iii Ste#268Dallas, TX 75203
Phone+1 214-947-4400
Fax+1 214-947-4404

Summary

Dr. Parvez Mantry is a gastroenterologist in Dallas, TX and is affiliated with multiple hospitals in the area, including Methodist Dallas Medical Center and CHRISTUS Mother Frances Hospital - Tyler. He received his medical degree from L. Tilak Municipal Medical College and has been in practice 22 years. He specializes in advanced endoscopic interventional and hepatology & liver transplantation and is experienced in hepatology. He has more than 50 publications and over 500 citings.

Education & Training

University of Rochester Medical CenterFellowship, Gastroenterology, 2000 - 2003
Westchester Medical CenterResidency, Internal Medicine, 1997 - 2000
L. Tilak Municipal Medical CollegeClass of 1995

Certifications & Licensure

TX State Medical License 2008 - 2025
FL State Medical License 2005 - 2011
NY State Medical License 2003 - 2008
American Board of Internal Medicine Transplant Hepatology

Clinical Trials

Wireless Capsule Endoscopy in Small-Bowel Crohn's Disease Start of enrollment: 2005 Jun 01
Withdrawn
Phase 1, Phase 2
Autoimmune Hepatitis Study Start of enrollment: 2006 Jan 01
Terminated
Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure Start of enrollment: 2013 Feb 01
Completed
Phase 3
Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy Start of enrollment: 2013 Apr 03
Terminated
Phase 4
Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection Start of enrollment: 2013 Jun 01
Unknown status
Phase 2
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Start of enrollment: 2015 Sep 22
TERMINATED
PHASE3
Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124 Start of enrollment: 2016 Jul 31
Withdrawn
Early Phase 1
TheraSphere & Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer Start of enrollment: 2014 May 22
Completed
Not Applicable
Mindfulness and Shared Decision Making Start of enrollment: 2018 Aug 15
Completed
CM-101 in PSC Patients -The SPRING Study Start of enrollment: 2020 Oct 01
Active, not recruiting
Phase 2
Roles: Contact
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement Start of enrollment: 2023 Jul 05
RECRUITING
PHASE2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Letter: Enhancing the Diagnostic Performance of the Oral Cholate Challenge Test: Implications for Avoidance of Potentially Unnecessary Endoscopy.
Tarek Hassanein, Andrew P Keaveny, Parvez Mantry, Mitchell Shiffman, Michael Leise
Alimentary Pharmacology & Therapeutics. 2025-03-29
Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosis: A randomized, placebo-controlled phase 2 trial.
Benjamin J Bruno, Joshua C Weavil, Jonathan Ogle, Nachiappan Chidambaram, Elizabeth J Carey
Hepatology. 2025-01-31
Editorial: Reading the cholate-A new gateway to portal hypertension and oesophageal varices: Authors' reply.
Tarek Hassanein, Andrew P Keaveny, Parvez Mantry, Alastair D Smith, Michael P McRae
Alimentary Pharmacology & Therapeutics. 2024-08-01

Press Mentions

Remdesivir Offers Hope for Hospitalized COVID-19 PatientsMay 7th, 2020